Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A pilot, open label, clinical trial using hydroxyzine in multiple sclerosis.

L Logothetis1, I A Mylonas, S Baloyannis

  • 1Department of Neurology, Aristotle University, AHEPA Hospital, Thessaloniki, Greece.

International Journal of Immunopathology and Pharmacology
|January 4, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurohormonal markers in chronic rhinosinusitis.

Journal of biological regulators and homeostatic agents·2021
Same author

Be aware of SARS-CoV-2 spike protein: There is more than meets the eye.

Journal of biological regulators and homeostatic agents·2021
Same author

Antibodies for COVID-19 - which, when and how long?

Journal of biological regulators and homeostatic agents·2021
Same author

COVID-19 and Multisystem Inflammatory Syndrome, or is it Mast Cell Activation Syndrome?

Journal of biological regulators and homeostatic agents·2020
Same author

IL-1 Superfamily Members and Periodontal Diseases.

Journal of dental research·2020
Same author

Dexamethasone for COVID-19? Not so fast.

Journal of biological regulators and homeostatic agents·2020

The antihistamine hydroxyzine, combined with caffeine, showed potential in stabilizing or improving neurological symptoms and mood in multiple sclerosis patients during a pilot study.

Area of Science:

  • Neuroimmunology
  • Demyelinating Diseases

Background:

  • Multiple sclerosis (MS) is an autoimmune disease characterized by myelin destruction.
  • Blood-brain barrier (BBB) disruption in MS may involve mast cell mediators like histamine.
  • Acute stress can trigger MS exacerbations, potentially via mast cell activation.

Purpose of the Study:

  • To investigate the efficacy of hydroxyzine, a histamine-1 (H1) receptor antagonist, as an adjuvant therapy for multiple sclerosis.
  • To assess the impact of hydroxyzine on neurological symptoms and mood in MS patients.

Main Methods:

  • An open-label, pilot clinical trial involving 20 patients with relapsing-remitting or relapsing-progressive MS.
  • Patients received oral hydroxyzine (100 mg/day) with caffeine (200 mg/day) for 12 months.

Related Experiment Videos

  • Disability scales were used for patient evaluation.

    • Main Results:

    • 75% of patients remained neurologically stable or showed improvement.
    • Mood improved in all but one patient.
    • Hydroxyzine was generally well-tolerated.

    Conclusions:

    • Hydroxyzine may serve as a beneficial adjuvant therapy for multiple sclerosis.
    • Further investigation in a larger, double-blind, placebo-controlled study is warranted due to the pilot nature and small sample size.